Expert Q&A: Labs Must Take a Greater Role in Guiding Clinicians About Abnormal Data
Lee Fleisher, MD, advocates for clearer interpretation of test results by medical laboratory scientists
Industry Buzz-lir
Subscribe today for access to
Articles and Reports
At-Home Genetic Testing: The Good, The Bad, and The Ugly
Direct-to-consumer (DTC) genetic testing has risen in popularity in recent years—but is it all it’s cracked up to be?
Clinical Lab Education: The Role of Virtual Reality
How virtual reality technologies can support clinical laboratory education efforts and what leaders should know about implementation
Industry Buzz: 2017-The Year in DX Mergers & Acquisitions
...
This content is for Paid Members only.
Register
Register
Already a member? Log in here
CMS Finalizes Controversial PAMA Fee Schedule
...
This content is for Paid Members only.
Register
Register
Already a member? Log in here
FDA Watch: New Policy Would Allow DTC Marketing of Genetic Tests without Premarket Approval
From - Laboratory Industry Report
For years, the lab industry has been pressing the FDA to relinquish its rigorous oversight of direct-to-consumer (DTC) genetic health tests…
CMS Ignores Flawed Processes, Finalizes 2018 PAMA Pricing; Labs Need to Take Immediate Action to Offset Impending Lean Times
By Kyle Fetter bio
The final 2018 clinical laboratory fee schedule (CLFS) is out, and it is evident that the argument that the Centers for Medicare & Medicaid Services (CMS) PAMA process was…
Outreach Labs Remain Profitable Despite Antiquated Systems & Lack of Exec Respect
From - Laboratory Industry Report
Hidden within the basement of your average hospital is a $24 million business, one that provides a top quality, must-have service and operates at a margin of…
FDA Watch: New Moves to Boost CLIA Transparency
...
This content is for Paid Members only.
Register
Register
Already a member? Log in here
Industry Trends: New Report Sheds Light on DX Tech Capital Flows
From - Laboratory Industry Report
The health care industry has raised $5 billion in venture fund investment in the first half of 2017 and is well on pace to smash the single year record of…
Draft 2018 CLFS Reveals Fundamental Flaws in PAMA Reporting Exercise; Time to Take Action
By Lâle White bio
As XIFIN predicted, the PAMA reporting exercise has resulted in significant proposed laboratory fee cuts. In fact…
Company of the Month: Interpace Diagnostics
...
This content is for Paid Members only.
Register
Register
Already a member? Log in here
Medicare Reimbursement: 4 Molecular Assays Score Big Coverage Wins
...
This content is for Paid Members only.
Register
Register
Already a member? Log in here